Pub Date : 2024-11-30DOI: 10.3390/curroncol31120560
Pauline Holmer, Brianna Henry, Jenny Duong, Oluwaseyi A Lawal, Miranda M Fidler-Benaoudia, Kathleen Reynolds, Gisela Michel, Vicky Lehmann, Fiona S M Schulte
Survivors of childhood cancer face reduced fertility, which can be a significant cause for concern. Our study aimed to assess the prevalence of fertility-related concerns and identify associated factors. Self-report data were collected with the Long-Term Survivor Questionnaire at the Alberta Children's Hospital's Long-Term Survivor Clinic (LTSC) between January 2021 and September 2023. Eligible participants were diagnosed before the age of 21 years, ≥2 years off therapy, and ≥13 years old. We analyzed fertility-related concerns cross-sectionally for the whole sample and longitudinally for a subsample of participants that completed three questionnaires. We included N = 311 survivors (49.2% female; mean age = 22.7 years, range = 13.9-42.1; mean time since diagnosis = 14.5 years, range = 2.7-38.4), of whom 21.2% reported fertility-related concerns. Those with additional health concerns and those who were sexually active were more likely to report fertility-related concerns, whereas lymphoma survivors were least likely to report concerns. In the subsample who completed three questionnaires (n = 80), 30% reported having concerns at least once, whereas 9% expressed persistent concerns. Fertility-related concerns are highly prevalent among young survivors of childhood cancer and warrant attention from healthcare professionals. Services that systematically address fertility-related concerns throughout long-term follow-up are urgently needed. These services should provide a space to discuss concerns, provide education, and initiate fertility consultations if desired.
{"title":"Fertility-Related Concerns in Long-Term Survivors of Childhood Cancer: A Canadian Cohort Study.","authors":"Pauline Holmer, Brianna Henry, Jenny Duong, Oluwaseyi A Lawal, Miranda M Fidler-Benaoudia, Kathleen Reynolds, Gisela Michel, Vicky Lehmann, Fiona S M Schulte","doi":"10.3390/curroncol31120560","DOIUrl":"10.3390/curroncol31120560","url":null,"abstract":"<p><p>Survivors of childhood cancer face reduced fertility, which can be a significant cause for concern. Our study aimed to assess the prevalence of fertility-related concerns and identify associated factors. Self-report data were collected with the Long-Term Survivor Questionnaire at the Alberta Children's Hospital's Long-Term Survivor Clinic (LTSC) between January 2021 and September 2023. Eligible participants were diagnosed before the age of 21 years, ≥2 years off therapy, and ≥13 years old. We analyzed fertility-related concerns cross-sectionally for the whole sample and longitudinally for a subsample of participants that completed three questionnaires. We included <i>N</i> = 311 survivors (49.2% female; mean age = 22.7 years, range = 13.9-42.1; mean time since diagnosis = 14.5 years, range = 2.7-38.4), of whom 21.2% reported fertility-related concerns. Those with additional health concerns and those who were sexually active were more likely to report fertility-related concerns, whereas lymphoma survivors were least likely to report concerns. In the subsample who completed three questionnaires (<i>n</i> = 80), 30% reported having concerns at least once, whereas 9% expressed persistent concerns. Fertility-related concerns are highly prevalent among young survivors of childhood cancer and warrant attention from healthcare professionals. Services that systematically address fertility-related concerns throughout long-term follow-up are urgently needed. These services should provide a space to discuss concerns, provide education, and initiate fertility consultations if desired.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7603-7612"},"PeriodicalIF":2.8,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-29DOI: 10.3390/curroncol31120559
Maebh Kenny-Jones, Paul Nankivell, Hisham Mehanna, Gozde Ozakinci
Cancer care is evolving, and digital resources are being introduced to support cancer patients throughout the cancer journey. Logistical concerns, such as health literacy and the emotional experience of cancer, need to be considered. Fear of cancer recurrence (FCR) and fear of cancer progression (FOP) are relevant emotional constructs that should be investigated. This scoping review explored two main objectives: first, the link between FCR/FOP and engagement with digital resources, and second, the link between FCR/FOP and health literacy. A database search was conducted separately for each objective. Relevant papers were identified, data were extracted, and a quality assessment was conducted. Objective 1 identified two relevant papers that suggested that higher levels of FCR were correlated with lower levels of engagement with digital resources. Objective 2 identified eight relevant papers that indicated that higher FCR/FOP is correlated with lower health literacy. However, one paper with a greater sample size and a more representative sample reported no significant relationship. There may be important relationships between the constructs of FCR/FOP, resource engagement, and health literacy and relationships may differ across cancer type and sex. However, research is limited. No studies examined the relationship between FOP and engagement or FCR/FOP and digital health literacy, and the number of studies identified was too limited to come to a firm conclusion. Further research is needed to understand the significance and relevance of these relationships.
{"title":"Fear of Cancer Recurrence and Fear of Cancer Progression, Digital Resource Engagement and Health Literacy: A Review.","authors":"Maebh Kenny-Jones, Paul Nankivell, Hisham Mehanna, Gozde Ozakinci","doi":"10.3390/curroncol31120559","DOIUrl":"10.3390/curroncol31120559","url":null,"abstract":"<p><p>Cancer care is evolving, and digital resources are being introduced to support cancer patients throughout the cancer journey. Logistical concerns, such as health literacy and the emotional experience of cancer, need to be considered. Fear of cancer recurrence (FCR) and fear of cancer progression (FOP) are relevant emotional constructs that should be investigated. This scoping review explored two main objectives: first, the link between FCR/FOP and engagement with digital resources, and second, the link between FCR/FOP and health literacy. A database search was conducted separately for each objective. Relevant papers were identified, data were extracted, and a quality assessment was conducted. Objective 1 identified two relevant papers that suggested that higher levels of FCR were correlated with lower levels of engagement with digital resources. Objective 2 identified eight relevant papers that indicated that higher FCR/FOP is correlated with lower health literacy. However, one paper with a greater sample size and a more representative sample reported no significant relationship. There may be important relationships between the constructs of FCR/FOP, resource engagement, and health literacy and relationships may differ across cancer type and sex. However, research is limited. No studies examined the relationship between FOP and engagement or FCR/FOP and digital health literacy, and the number of studies identified was too limited to come to a firm conclusion. Further research is needed to understand the significance and relevance of these relationships.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7586-7602"},"PeriodicalIF":2.8,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-28DOI: 10.3390/curroncol31120558
Carly M Cooke, M Ege Babadagli, Hillary Wilson, Vimoj J Nair, Krystine Lupe, Shawn Malone, Laura Burgess, Wylam Faught, Rajiv Samant, Tien Le
(1) Background: The objectives of this study were to assess survival of patients with a diagnosis of brain metastases secondary to gynaecologic malignancy and the impact of clinicopathological factors on prognosis in this population. (2) Methods: A retrospective cohort of patients with gynaecologic cancers diagnosed with brain metastases treated with radiation at a tertiary care centre from 1 January 2004 until 30 September 2023 was studied. Kaplan-Meier method and log-rank test were used to evaluate survival, and cox regression was used to identify significant predictive factors of survival. (3) Results: In total, 103 patients were included in this study. Median age at diagnosis of brain metastases was 59 (range 30-94). Median survival time following diagnosis of brain metastases was 3.6 months (range 0.4-183.8). Survival was significantly longer for patients treated with surgery combined with radiation compared to radiation alone and with stereotactic radiosurgery (SRS) compared to whole brain radiation therapy (WBRT). Cox regression revealed that primary ovarian malignancy, extracranial disease at diagnosis, and ≥3 brain metastases were associated with poorer prognosis, and complete response to prior treatment was associated with more favourable prognosis. (4) Conclusions: Data from this study will assist in providing evidence-based prognostic information to patients with gynaecologic malignancy diagnosed with brain metastases.
{"title":"Brain Metastases in Gynaecologic Cancer: A Retrospective Cohort Study Evaluating Treatment Outcomes, Prognostic Factors, and Overall Survival.","authors":"Carly M Cooke, M Ege Babadagli, Hillary Wilson, Vimoj J Nair, Krystine Lupe, Shawn Malone, Laura Burgess, Wylam Faught, Rajiv Samant, Tien Le","doi":"10.3390/curroncol31120558","DOIUrl":"10.3390/curroncol31120558","url":null,"abstract":"<p><p>(1) Background: The objectives of this study were to assess survival of patients with a diagnosis of brain metastases secondary to gynaecologic malignancy and the impact of clinicopathological factors on prognosis in this population. (2) Methods: A retrospective cohort of patients with gynaecologic cancers diagnosed with brain metastases treated with radiation at a tertiary care centre from 1 January 2004 until 30 September 2023 was studied. Kaplan-Meier method and log-rank test were used to evaluate survival, and cox regression was used to identify significant predictive factors of survival. (3) Results: In total, 103 patients were included in this study. Median age at diagnosis of brain metastases was 59 (range 30-94). Median survival time following diagnosis of brain metastases was 3.6 months (range 0.4-183.8). Survival was significantly longer for patients treated with surgery combined with radiation compared to radiation alone and with stereotactic radiosurgery (SRS) compared to whole brain radiation therapy (WBRT). Cox regression revealed that primary ovarian malignancy, extracranial disease at diagnosis, and ≥3 brain metastases were associated with poorer prognosis, and complete response to prior treatment was associated with more favourable prognosis. (4) Conclusions: Data from this study will assist in providing evidence-based prognostic information to patients with gynaecologic malignancy diagnosed with brain metastases.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7575-7585"},"PeriodicalIF":2.8,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674415/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-27DOI: 10.3390/curroncol31120557
Calogero Cipolla, Vittorio Gebbia, Eleonora D'Agati, Martina Greco, Chiara Mesi, Giuseppa Scandurra, Daniela Sambataro, Maria Rosaria Valerio
Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer cases. Sentinel lymph node biopsy (SLNB) has emerged as a less invasive alternative to axillary lymph node dissection (ALND) for axillary staging in breast cancer, offering reduced morbidity and comparable accuracy. However, the application of SLNB in MBC remains underexplored, with limited male-specific data and treatment protocols often extrapolated from female breast cancer studies. Available evidence suggests that SLNB in men demonstrates high diagnostic accuracy, with low false-negative rates and a high sentinel lymph node identification rate. Despite this, there is ongoing debate about its long-term impact on clinical outcomes, particularly for patients with sentinel node metastasis, where ALND may still provide superior survival outcomes in some cases. Predictive tools are being developed to identify better patients who may benefit from SLNB alone, potentially reducing the need for more invasive procedures. As the role of SLNB continues to evolve in MBC management, further prospective research is needed to refine its application and assess its long-term oncologic outcomes.
{"title":"Accuracy and Outcomes of Sentinel Lymph Node Biopsy in Male with Breast Cancer: A Narrative Review and Expert Opinion.","authors":"Calogero Cipolla, Vittorio Gebbia, Eleonora D'Agati, Martina Greco, Chiara Mesi, Giuseppa Scandurra, Daniela Sambataro, Maria Rosaria Valerio","doi":"10.3390/curroncol31120557","DOIUrl":"10.3390/curroncol31120557","url":null,"abstract":"<p><p>Male breast cancer (MBC) is a rare disease, accounting for less than 1% of all breast cancer cases. Sentinel lymph node biopsy (SLNB) has emerged as a less invasive alternative to axillary lymph node dissection (ALND) for axillary staging in breast cancer, offering reduced morbidity and comparable accuracy. However, the application of SLNB in MBC remains underexplored, with limited male-specific data and treatment protocols often extrapolated from female breast cancer studies. Available evidence suggests that SLNB in men demonstrates high diagnostic accuracy, with low false-negative rates and a high sentinel lymph node identification rate. Despite this, there is ongoing debate about its long-term impact on clinical outcomes, particularly for patients with sentinel node metastasis, where ALND may still provide superior survival outcomes in some cases. Predictive tools are being developed to identify better patients who may benefit from SLNB alone, potentially reducing the need for more invasive procedures. As the role of SLNB continues to evolve in MBC management, further prospective research is needed to refine its application and assess its long-term oncologic outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7566-7574"},"PeriodicalIF":2.8,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674126/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objectives: This article reports a rare case of primary central nervous system lymphoma (PCNSL) found in a patient with thyroid cancer after surgery.
Methods: The patient was initially misdiagnosed with brain metastases, and the diagnosis of PCNSL was later confirmed by pathology.
Results: The analysis of this case and review of the relevant literature explores the possible mechanisms of the coexistence of thyroid cancer and PCNSL, as well as their diagnostic, differential diagnostic, and therapeutic challenges.
Conclusions: The article suggests a possible correlation between the coexistence of multiple cancers and autoimmune diseases and emphasizes that disease cannot be only considered in a monolithic way.
{"title":"Primary Central Nervous System Lymphoma (PCNSL) Following Thyroid Cancer Surgery: A Case Report of Misdiagnosed Brain Metastasis and Literature Review.","authors":"Yilin Li, Tingyu Liang, Hao Xing, Yu Wang, Kuanyu Wang, Wenbin Ma","doi":"10.3390/curroncol31120556","DOIUrl":"10.3390/curroncol31120556","url":null,"abstract":"<p><p><b>Objectives:</b> This article reports a rare case of primary central nervous system lymphoma (PCNSL) found in a patient with thyroid cancer after surgery.</p><p><strong>Methods: </strong>The patient was initially misdiagnosed with brain metastases, and the diagnosis of PCNSL was later confirmed by pathology.</p><p><strong>Results: </strong>The analysis of this case and review of the relevant literature explores the possible mechanisms of the coexistence of thyroid cancer and PCNSL, as well as their diagnostic, differential diagnostic, and therapeutic challenges.</p><p><strong>Conclusions: </strong>The article suggests a possible correlation between the coexistence of multiple cancers and autoimmune diseases and emphasizes that disease cannot be only considered in a monolithic way.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7555-7565"},"PeriodicalIF":2.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-26DOI: 10.3390/curroncol31120555
Nicolas Papalexis, Giuliano Peta, Michela Carta, Simone Quarchioni, Maddalena Di Carlo, Marco Miceli, Giancarlo Facchini
Background: Arterial embolization is a minimally invasive treatment that occludes blood vessels supplying pathological tissue. Developed to control bleeding without surgery, it has evolved over decades and is now applied in musculoskeletal oncology as a preoperative treatment, palliative care, or standalone therapy for select tumors. Recently, its use has expanded globally in treating chronic pain syndromes and osteoarthritis.
Materials and methods: We reviewed the literature on arterial embolization in various musculoskeletal conditions. The focus was on established oncologic indications for primary and metastatic bone or soft tissue tumors, and emerging evidence on degenerative diseases like osteoarthritis, inflammatory musculoskeletal pathology, and intractable pain. Emphasis was placed on leading studies regarding efficacy, complications, and recurrence rates.
Discussion: Arterial embolization has progressed from bleeding control to a versatile therapeutic option in musculoskeletal medicine. It offers symptom relief, reduces tumor size, and improves quality of life. Applications include oncologic interventions and management of degenerative and inflammatory conditions. Despite its benefits, variations in complications and recurrence rates highlight the need for standardized protocols and further research.
Conclusions: Arterial embolization is a safe and effective minimally invasive tool in the multidisciplinary management of a wide range of musculoskeletal pathologies. Ongoing research is crucial to understand long-term efficacy, optimize protocols, and broaden its applications.
{"title":"How Arterial Embolization Is Transforming Treatment of Oncologic and Degenerative Musculoskeletal Disease.","authors":"Nicolas Papalexis, Giuliano Peta, Michela Carta, Simone Quarchioni, Maddalena Di Carlo, Marco Miceli, Giancarlo Facchini","doi":"10.3390/curroncol31120555","DOIUrl":"10.3390/curroncol31120555","url":null,"abstract":"<p><strong>Background: </strong>Arterial embolization is a minimally invasive treatment that occludes blood vessels supplying pathological tissue. Developed to control bleeding without surgery, it has evolved over decades and is now applied in musculoskeletal oncology as a preoperative treatment, palliative care, or standalone therapy for select tumors. Recently, its use has expanded globally in treating chronic pain syndromes and osteoarthritis.</p><p><strong>Materials and methods: </strong>We reviewed the literature on arterial embolization in various musculoskeletal conditions. The focus was on established oncologic indications for primary and metastatic bone or soft tissue tumors, and emerging evidence on degenerative diseases like osteoarthritis, inflammatory musculoskeletal pathology, and intractable pain. Emphasis was placed on leading studies regarding efficacy, complications, and recurrence rates.</p><p><strong>Discussion: </strong>Arterial embolization has progressed from bleeding control to a versatile therapeutic option in musculoskeletal medicine. It offers symptom relief, reduces tumor size, and improves quality of life. Applications include oncologic interventions and management of degenerative and inflammatory conditions. Despite its benefits, variations in complications and recurrence rates highlight the need for standardized protocols and further research.</p><p><strong>Conclusions: </strong>Arterial embolization is a safe and effective minimally invasive tool in the multidisciplinary management of a wide range of musculoskeletal pathologies. Ongoing research is crucial to understand long-term efficacy, optimize protocols, and broaden its applications.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7523-7554"},"PeriodicalIF":2.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-26DOI: 10.3390/curroncol31120554
Grace Keane, Rob van Rooij, Marnix Lam, Arthur Braat, Maarten Smits, Hugo de Jong
In same-day radioembolization, 99mTc-MAA SPECT/CT, 90Y radioembolization, and post-treatment 90Y SPECT/CT procedures are conducted on the same-day, resulting in a dual-isotope environment of 90Y and 99mTc during post-treatment imaging. This study aimed to quantify the impact of 99mTc on 90Y bremsstrahlung-SPECT/CT image quality and to establish an optimised imaging protocol for both clinical practice, and with advanced reconstruction techniques. Utilising a NEMA IQ phantom, contrast recovery coefficients (CRCs) were measured to evaluate the 90Y image quality degradation caused by 99mTc. SPECT/CT scans of 90Y-only and 90Y with varying amounts of 99mTc were conducted using a standard protocol (90-120 keV energy window, high-energy collimator) and various dual-isotope protocols. The standard protocol resulted in a marked CRC reduction, with the largest sphere's CRC decreasing from 0.21 (90Y-only) to 0.05 when 99mTc activity was 5% of 90Y. For an optimised protocol (160-200 keV energy window, high-energy collimator) CRC values were 0.16 for 90Y-only and 0.15 for 90Y+99mTc. The highest CRC values were achieved with an advanced Monte Carlo-based reconstruction, showing 0.58 for 90Y-only and 0.46 for 90Y+99mTc. Image quality degradation was noted in dual-isotope settings even when using an optimised protocol. Advanced reconstruction techniques markedly improved post-treatment image quality.
当日放射栓塞,99mTc- maa SPECT/CT、90Y放射栓塞、治疗后90Y SPECT/CT在同一天进行,导致治疗后成像90Y和99mTc双同位素环境。本研究旨在量化99mTc对90Y形变spect /CT图像质量的影响,并为临床实践和先进的重建技术建立优化的成像方案。利用NEMA IQ模体,测量对比度恢复系数(crc)以评估99mTc引起的90Y图像质量下降。使用标准方案(90-120 keV能量窗,高能准直器)和各种双同位素方案对90Y-only和90Y进行不同99mTc量的SPECT/CT扫描。标准方案导致CRC显著降低,当99mTc活性为90Y的5%时,最大球体的CRC从0.21(仅90Y)降至0.05。对于优化的协议(160-200 keV能量窗口,高能准直器),仅90Y的CRC值为0.16,90Y+99mTc的CRC值为0.15。先进的蒙特卡罗重建获得了最高的CRC值,仅90Y为0.58,90Y+99mTc为0.46。在双同位素设置中,即使使用优化的协议,图像质量也会下降。先进的重建技术显著提高了处理后的图像质量。
{"title":"An Evaluation of 90Y Bremsstrahlung SPECT Image Quality in the Presence of 99mTc: A Technical Perspective on Same-Day Radioembolization.","authors":"Grace Keane, Rob van Rooij, Marnix Lam, Arthur Braat, Maarten Smits, Hugo de Jong","doi":"10.3390/curroncol31120554","DOIUrl":"10.3390/curroncol31120554","url":null,"abstract":"<p><p>In same-day radioembolization, 99mTc-MAA SPECT/CT, 90Y radioembolization, and post-treatment 90Y SPECT/CT procedures are conducted on the same-day, resulting in a dual-isotope environment of 90Y and 99mTc during post-treatment imaging. This study aimed to quantify the impact of 99mTc on 90Y bremsstrahlung-SPECT/CT image quality and to establish an optimised imaging protocol for both clinical practice, and with advanced reconstruction techniques. Utilising a NEMA IQ phantom, contrast recovery coefficients (CRCs) were measured to evaluate the 90Y image quality degradation caused by 99mTc. SPECT/CT scans of 90Y-only and 90Y with varying amounts of 99mTc were conducted using a standard protocol (90-120 keV energy window, high-energy collimator) and various dual-isotope protocols. The standard protocol resulted in a marked CRC reduction, with the largest sphere's CRC decreasing from 0.21 (90Y-only) to 0.05 when 99mTc activity was 5% of 90Y. For an optimised protocol (160-200 keV energy window, high-energy collimator) CRC values were 0.16 for 90Y-only and 0.15 for 90Y+99mTc. The highest CRC values were achieved with an advanced Monte Carlo-based reconstruction, showing 0.58 for 90Y-only and 0.46 for 90Y+99mTc. Image quality degradation was noted in dual-isotope settings even when using an optimised protocol. Advanced reconstruction techniques markedly improved post-treatment image quality.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7511-7522"},"PeriodicalIF":2.8,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-25DOI: 10.3390/curroncol31120553
Hyunseok Jee
Colorectal cancer (CRC) is the third most common cancer globally. Therefore, this study aims to examine data from the National Health Insurance Sharing Service (NHISS) to investigate factors influencing colon cancer incidence, focusing on key variables and optimal cutoff points. The patient cohort from the NHISS database included 1,120,377 individuals aged 1-85 years. CRC data were retrieved using diagnostic codes from the Korean Standard Classification of Diseases and Causes of Death. Analyses included logistic regression and receiver operating characteristic curve assessments. In this retrospective cohort study, 1,120,377 patients were analyzed for over 10 years, including 2802 with CRC via propensity score matching (PSM). Key risk factors were blood pressure, fasting blood sugar, liver somatic index, alcohol consumption, smoking duration, and hemoglobin levels. Patients with CRC showed sex differences in gamma-glutamyl transpeptidase (GGT). High-intensity exercise (3 days/week) reduced CRC risk by 26% (p < 0.05). Optimal threshold points for GGT and Charlson Comorbidity Index (CCI) were 23.50 U/L (AUC, 0.52) and 1.50 (AUC, 0.58), respectively. CCI scores were higher in patients with cancer, especially men with peptic ulcers and both sexes with metastatic cancer (p < 0.01). Our findings reveal new risk factors and interventions, including tailored exercise programs for CRC management, highlighting the importance of enhanced preventive strategies and personalized care.
{"title":"Key Risk Factors, Sex Differences, and the Influence of High-Intensity Exercise on Colorectal Carcinogenesis: A 10-Year Cohort Study Based on 1,120,377 Individuals from the NHISS Data.","authors":"Hyunseok Jee","doi":"10.3390/curroncol31120553","DOIUrl":"10.3390/curroncol31120553","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is the third most common cancer globally. Therefore, this study aims to examine data from the National Health Insurance Sharing Service (NHISS) to investigate factors influencing colon cancer incidence, focusing on key variables and optimal cutoff points. The patient cohort from the NHISS database included 1,120,377 individuals aged 1-85 years. CRC data were retrieved using diagnostic codes from the Korean Standard Classification of Diseases and Causes of Death. Analyses included logistic regression and receiver operating characteristic curve assessments. In this retrospective cohort study, 1,120,377 patients were analyzed for over 10 years, including 2802 with CRC via propensity score matching (PSM). Key risk factors were blood pressure, fasting blood sugar, liver somatic index, alcohol consumption, smoking duration, and hemoglobin levels. Patients with CRC showed sex differences in gamma-glutamyl transpeptidase (GGT). High-intensity exercise (3 days/week) reduced CRC risk by 26% (<i>p</i> < 0.05). Optimal threshold points for GGT and Charlson Comorbidity Index (CCI) were 23.50 U/L (AUC, 0.52) and 1.50 (AUC, 0.58), respectively. CCI scores were higher in patients with cancer, especially men with peptic ulcers and both sexes with metastatic cancer (<i>p</i> < 0.01). Our findings reveal new risk factors and interventions, including tailored exercise programs for CRC management, highlighting the importance of enhanced preventive strategies and personalized care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7494-7510"},"PeriodicalIF":2.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-25DOI: 10.3390/curroncol31120552
Nur Rahmah Rasyid, Upik Anderiani Miskad, Muhammad Husni Cangara, Syarifuddin Wahid, Djumadi Achmad, Suryani Tawali, Mardiati Mardiati
Aim: Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate. Tumor-infiltrating lymphocytes (TILs) play a crucial role in the immune response against tumors. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are key immune checkpoints regulating T cells in the tumor microenvironment. This study aimed to assess the relationships among PD-1 expression on TILs, PD-L1 expression in tumors, and TIL grading in colorectal adenocarcinoma.
Methods: A cross-sectional design was employed to analyze 130 colorectal adenocarcinoma samples. The expression of PD-1 and PD-L1 was assessed through immunohistochemistry. A semi-quantitative scoring system was applied. Statistical analysis with the chi-square test was performed to explore correlations, with the data analyzed in SPSS version 27.
Results: PD-1 expression on TILs significantly correlated with a higher TIL grading (p < 0.001), while PD-L1 expression in tumors showed an inverse correlation with TIL grading (p < 0.001).
Conclusions: The expression of PD-1 on TILs and PD-L1 on tumor cells correlated significantly with the grading of TILs in colorectal adenocarcinoma. This finding shows potential as a predictive biomarker for PD-1/PD-L1 blockade therapy. Further studies are needed to strengthen these results.
目的:结直肠癌(CRC)是一种常见的恶性肿瘤,死亡率高。肿瘤浸润淋巴细胞(til)在肿瘤免疫应答中起着至关重要的作用。程序性死亡-1 (PD-1)和程序性死亡配体1 (PD-L1)是肿瘤微环境中调节T细胞的关键免疫检查点。本研究旨在评估PD-1在TIL上的表达、肿瘤中PD-L1的表达以及结直肠癌TIL分级之间的关系。方法:采用横断面设计对130例结直肠癌样本进行分析。免疫组化检测PD-1和PD-L1的表达。采用半定量评分系统。采用卡方检验进行统计学分析以探讨相关性,数据采用SPSS version 27进行分析。结果:肿瘤组织中PD-1表达与TIL分级呈正相关(p < 0.001),肿瘤组织中PD-L1表达与TIL分级呈负相关(p < 0.001)。结论:肿瘤细胞上PD-1和PD-L1的表达与结直肠癌TILs的分级有显著相关性。这一发现显示了作为PD-1/PD-L1阻断治疗的预测性生物标志物的潜力。需要进一步的研究来加强这些结果。
{"title":"The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading.","authors":"Nur Rahmah Rasyid, Upik Anderiani Miskad, Muhammad Husni Cangara, Syarifuddin Wahid, Djumadi Achmad, Suryani Tawali, Mardiati Mardiati","doi":"10.3390/curroncol31120552","DOIUrl":"10.3390/curroncol31120552","url":null,"abstract":"<p><strong>Aim: </strong>Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate. Tumor-infiltrating lymphocytes (TILs) play a crucial role in the immune response against tumors. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are key immune checkpoints regulating T cells in the tumor microenvironment. This study aimed to assess the relationships among PD-1 expression on TILs, PD-L1 expression in tumors, and TIL grading in colorectal adenocarcinoma.</p><p><strong>Methods: </strong>A cross-sectional design was employed to analyze 130 colorectal adenocarcinoma samples. The expression of PD-1 and PD-L1 was assessed through immunohistochemistry. A semi-quantitative scoring system was applied. Statistical analysis with the chi-square test was performed to explore correlations, with the data analyzed in SPSS version 27.</p><p><strong>Results: </strong>PD-1 expression on TILs significantly correlated with a higher TIL grading (<i>p</i> < 0.001), while PD-L1 expression in tumors showed an inverse correlation with TIL grading (<i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>The expression of PD-1 on TILs and PD-L1 on tumor cells correlated significantly with the grading of TILs in colorectal adenocarcinoma. This finding shows potential as a predictive biomarker for PD-1/PD-L1 blockade therapy. Further studies are needed to strengthen these results.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7476-7493"},"PeriodicalIF":2.8,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-24DOI: 10.3390/curroncol31120551
Gianluca Scalia, Gianluca Ferini, Zubayer Shams, Francesca Graziano, Giancarlo Ponzo, Eliana Giurato, Maria Grazia Galasso, Vitalinda Pumo, Martina Caruso, Gianluca Galvano, Salvatore Marrone, Jessica Naimo, Giovanni Federico Nicoletti, Giuseppe Emmanuele Umana
(1) Background: Testicular cancer, although accounting for only 0.5% to 1% of all solid male cancers, is the most common malignancy in males aged 15 to 35 years. Non-seminomatous germ cell tumors (NSGCT) represent nearly half of all testicular germ cell tumors and are associated with a more aggressive clinical course. Spinal metastases, while rare, pose significant challenges due to their potential to cause spinal cord compression, neurological deficits, and severe pain. This systematic review aims to evaluate prognosis and treatment approaches for spinal metastases in NSGCT, with a focus on multidisciplinary care and treatment outcomes. (2) Methods: A systematic review was conducted following PRISMA guidelines. PubMed, Scopus, and Embase were searched on 18 September 2024, using the Boolean search strategy [(Nonseminomatous germ cell tumor (NSGCT) AND (spinal OR vertebral metastases)]. Case reports, case series, and cohort studies providing detailed patient data were included. Data on patient demographics, tumor histology, metastatic site, treatments, and outcomes were extracted for analysis. (3) Results: A total of 164 cases of NSGCT with spinal metastases were analyzed, with patients aged 23 to 40 years (median: 31.5 years). The lumbar spine was involved in all cases, and spinal cord compression occurred in 59.8% of patients, often causing severe neurological symptoms such as cauda equina syndrome. Chemotherapy, primarily cisplatin-based, was administered in all cases, while surgical interventions, including laminectomy and vertebrectomy, were performed in cases of spinal compression and instability. Complete remission occurred in only 2.4% of patients. Progressive improvement was observed in 56.7% of cases, while 20.1% of patients died. Outcomes varied, highlighting the importance of individualized, multidisciplinary care to manage both systemic and localized disease. (4) Conclusions: Spinal metastases in NSGCT represent a complex clinical scenario, requiring a combination of chemotherapy, surgery, and in some cases, radiotherapy. Chemotherapy remains essential, but surgery is critical for addressing spinal compression and instability. A multidisciplinary approach is vital for optimizing outcomes, as prognosis is variable, with some patients achieving improvement while others face progressive disease or death. Further research is needed to refine the role of radiotherapy and improve long-term treatment strategies for this rare complication.
{"title":"Spinal Metastases in Non-Seminomatous Germ Cell Testicular Tumors: Prognosis and Integrated Therapeutic Approaches-A Systematic Review with an Institutional Case Illustration.","authors":"Gianluca Scalia, Gianluca Ferini, Zubayer Shams, Francesca Graziano, Giancarlo Ponzo, Eliana Giurato, Maria Grazia Galasso, Vitalinda Pumo, Martina Caruso, Gianluca Galvano, Salvatore Marrone, Jessica Naimo, Giovanni Federico Nicoletti, Giuseppe Emmanuele Umana","doi":"10.3390/curroncol31120551","DOIUrl":"10.3390/curroncol31120551","url":null,"abstract":"<p><p>(1) Background: Testicular cancer, although accounting for only 0.5% to 1% of all solid male cancers, is the most common malignancy in males aged 15 to 35 years. Non-seminomatous germ cell tumors (NSGCT) represent nearly half of all testicular germ cell tumors and are associated with a more aggressive clinical course. Spinal metastases, while rare, pose significant challenges due to their potential to cause spinal cord compression, neurological deficits, and severe pain. This systematic review aims to evaluate prognosis and treatment approaches for spinal metastases in NSGCT, with a focus on multidisciplinary care and treatment outcomes. (2) Methods: A systematic review was conducted following PRISMA guidelines. PubMed, Scopus, and Embase were searched on 18 September 2024, using the Boolean search strategy [(Nonseminomatous germ cell tumor (NSGCT) AND (spinal OR vertebral metastases)]. Case reports, case series, and cohort studies providing detailed patient data were included. Data on patient demographics, tumor histology, metastatic site, treatments, and outcomes were extracted for analysis. (3) Results: A total of 164 cases of NSGCT with spinal metastases were analyzed, with patients aged 23 to 40 years (median: 31.5 years). The lumbar spine was involved in all cases, and spinal cord compression occurred in 59.8% of patients, often causing severe neurological symptoms such as cauda equina syndrome. Chemotherapy, primarily cisplatin-based, was administered in all cases, while surgical interventions, including laminectomy and vertebrectomy, were performed in cases of spinal compression and instability. Complete remission occurred in only 2.4% of patients. Progressive improvement was observed in 56.7% of cases, while 20.1% of patients died. Outcomes varied, highlighting the importance of individualized, multidisciplinary care to manage both systemic and localized disease. (4) Conclusions: Spinal metastases in NSGCT represent a complex clinical scenario, requiring a combination of chemotherapy, surgery, and in some cases, radiotherapy. Chemotherapy remains essential, but surgery is critical for addressing spinal compression and instability. A multidisciplinary approach is vital for optimizing outcomes, as prognosis is variable, with some patients achieving improvement while others face progressive disease or death. Further research is needed to refine the role of radiotherapy and improve long-term treatment strategies for this rare complication.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"31 12","pages":"7459-7475"},"PeriodicalIF":2.8,"publicationDate":"2024-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11674372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}